These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32471486)

  • 41. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
    Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
    Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exclusive induction of tau2 epitope in microglia/macrophages in inflammatory lesions-tautwopathy distinct from degenerative tauopathies.
    Uchihara T; Duyckaerts C; Seilhean D; Nakamura A; Lazarini F; Hauw JJ
    Acta Neuropathol; 2005 Feb; 109(2):159-64. PubMed ID: 15549333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
    Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Partial reduction of microglia does not affect tau pathology in aged mice.
    Bennett RE; Bryant A; Hu M; Robbins AB; Hopp SC; Hyman BT
    J Neuroinflammation; 2018 Nov; 15(1):311. PubMed ID: 30413160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The blockage of the Nogo/NgR signal pathway in microglia alleviates the formation of Aβ plaques and tau phosphorylation in APP/PS1 transgenic mice.
    Fang Y; Yao L; Li C; Wang J; Wang J; Chen S; Zhou XF; Liao H
    J Neuroinflammation; 2016 Mar; 13(1):56. PubMed ID: 26939570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microglial tau undergoes phosphorylation-independent modification after ischemia.
    Uchihara T; Nakamura A; Arai T; Ikeda K; Tsuchiya K
    Glia; 2004 Jan; 45(2):180-7. PubMed ID: 14730711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A common antigenic motif recognized by naturally occurring human V
    Apetri A; Crespo R; Juraszek J; Pascual G; Janson R; Zhu X; Zhang H; Keogh E; Holland T; Wadia J; Verveen H; Siregar B; Mrosek M; Taggenbrock R; Ameijde J; Inganäs H; van Winsen M; Koldijk MH; Zuijdgeest D; Borgers M; Dockx K; Stoop EJM; Yu W; Brinkman-van der Linden EC; Ummenthum K; van Kolen K; Mercken M; Steinbacher S; de Marco D; Hoozemans JJ; Wilson IA; Koudstaal W; Goudsmit J
    Acta Neuropathol Commun; 2018 May; 6(1):43. PubMed ID: 29855358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.
    Van Kolen K; Malia TJ; Theunis C; Nanjunda R; Teplyakov A; Ernst R; Wu SJ; Luo J; Borgers M; Vandermeeren M; Bottelbergs A; Wintmolders C; Lacy E; Maurin H; Larsen P; Willems R; Van De Casteele T; Triana-Baltzer G; Slemmon R; Galpern W; Trojanowski JQ; Sun H; Mercken MH
    J Alzheimers Dis; 2020; 77(4):1397-1416. PubMed ID: 32894244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Depletion of microglia and inhibition of exosome synthesis halt tau propagation.
    Asai H; Ikezu S; Tsunoda S; Medalla M; Luebke J; Haydar T; Wolozin B; Butovsky O; Kügler S; Ikezu T
    Nat Neurosci; 2015 Nov; 18(11):1584-93. PubMed ID: 26436904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
    Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
    Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration.
    Gratuze M; Leyns CE; Sauerbeck AD; St-Pierre MK; Xiong M; Kim N; Serrano JR; Tremblay MÈ; Kummer TT; Colonna M; Ulrich JD; Holtzman DM
    J Clin Invest; 2020 Sep; 130(9):4954-4968. PubMed ID: 32544086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics.
    Rosseels J; Van den Brande J; Violet M; Jacobs D; Grognet P; Lopez J; Huvent I; Caldara M; Swinnen E; Papegaey A; Caillierez R; Buée-Scherrer V; Engelborghs S; Lippens G; Colin M; Buée L; Galas MC; Vanmechelen E; Winderickx J
    J Biol Chem; 2015 Feb; 290(7):4059-74. PubMed ID: 25540200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aβ-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-Aβ single chain variable fragment in combination with an apoE mimetic peptide.
    Montoliu-Gaya L; Mulder SD; Herrebout MAC; Baayen JC; Villegas S; Veerhuis R
    Mol Cell Neurosci; 2018 Jun; 89():49-59. PubMed ID: 29625180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau.
    Courade JP; Angers R; Mairet-Coello G; Pacico N; Tyson K; Lightwood D; Munro R; McMillan D; Griffin R; Baker T; Starkie D; Nan R; Westwood M; Mushikiwabo ML; Jung S; Odede G; Sweeney B; Popplewell A; Burgess G; Downey P; Citron M
    Acta Neuropathol; 2018 Nov; 136(5):729-745. PubMed ID: 30238240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurodegeneration Enhances the Development of Arthritis.
    Lang SC; Harre U; Purohit P; Dietel K; Kienhöfer D; Hahn J; Baum W; Herrmann M; Schett G; Mielenz D
    J Immunol; 2017 Mar; 198(6):2394-2402. PubMed ID: 28188247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
    Ishikawa A; Tokunaga M; Maeda J; Minamihisamatsu T; Shimojo M; Takuwa H; Ono M; Ni R; Hirano S; Kuwabara S; Ji B; Zhang MR; Aoki I; Suhara T; Higuchi M; Sahara N
    J Alzheimers Dis; 2018; 61(3):1037-1052. PubMed ID: 29332041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.